SaurabhChhabraMDMS

Oncology • Scottsdale, AZ

Hematologic Oncology

Senior Associate Consultant, Mayo Clinic, Phoenix, AZ

Join to view full profile

Dr. Chhabra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chhabra's full profile

Already have an account?

Office
13400 E Shea Blvd
Scottsdale, AZ 85259
Phone+1 480-301-8000

Summary

Dr. Saurabh Chhabra is a hematologist/oncologist in Phoenix, AZ and is affiliated with Mayo Clinic. He received his medical degree from Delhi University and has been in practice for over 20 years. He specializes in hematologic/oncology and is experienced in hematologic oncology, hematopoietic stem cell transplantation, bone marrow transplantation, CAR-T therapy, and multiple myeloma. He has more than 170 publications and over 6000 citations to his credit.

Education & Training

CTSI of Southeastern WisconsinM.S., CTS, 2016 - 2018
Stanford Health CareFellowship, Blood & Bone Marrow Transplant, 2011 - 2012
Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2008 - 2011
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 2006 - 2008
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2005 - 2006
Delhi University College of Medical SciencesClass of 2001

Certifications & Licensure

CA State Medical License 2011 - 2026
AZ State Medical License 2022 - 2025
SC State Medical License 2012 - 2025
WI State Medical License 2016 - 2025
NJ State Medical License 2008 - 2011
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients Start of enrollment: 2013 Aug 01
Completed
Phase 3
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Start of enrollment: 2014 Aug 01
Completed
Phase 2
Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Start of enrollment: 2015 Jun 01
Completed

Publications & Presentations

PubMed

Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy.
Luciano J Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R Dholaria, Kelly N Godby
Blood Cancer Journal. 2025-02-05
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.
Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum
Journal for Immunotherapy of Cancer. 2025-01-28
A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT.
Zachariah DeFilipp, Haesook T Kim, Guang-Shing Cheng, Betty K Hamilton, Saurabh Chhabra
Blood Advances. 2025-01-28

Journal Articles

Second Primary Malignancy After Multiple Myeloma‐Population Trends and Cause‐Specific Mortality
Parameswaran Hari, Luciano J Costa, Saurabh Chhabra, Kelly N Godby, British Journal of Haematology

Abstracts/Posters

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Novel Prognostic Scoring System for Autologous Hematopoietic Cell Transplantation (AHCT) in Multiple Myeloma (MM)
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT)
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Population-Level Trends in Early Mortality and Overall Survival of Patients with Multiple Myeloma. Are We Facing Stagnation?
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Di...
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Saurabh Chhabra, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018